LY3009120, also known as DP-4978, is potent and selective pan-RAF inhibitor with potential anticancer activity. LY3009120 showed activities against BRaf or Ras mutant tumor cells . LY3009120 binds to ARaf, BRaf and CRaf isoforms with similar affinity in cells with activating mutations of BRaf or KRas. LY3009120 induces minimal paradoxical pathway activation in NRas or KRas mutant cells. LY3009120 inhibits MEK phosphorylation and cell proliferation in vitro, and exhibits anti-tumor activity in multiple xenograft models carrying mutations in BRaf, NRas or KRas.
Raf Inhibitors Related Products:
Vemurafenib; PLX-4720; Debrafenib; Regorafenib; GDC-0879; RAF265 (CHIR-265); AZ-628; SB590885; ZM 336372; TAK-632; B-Raf IN 1; AZ304; Dabrafenib Mesylate; RAF709; RO5126766; Doramapimod; MLN2480; GW5074